Published on April 16, 2026
Cambridge-based STORM Therapeutics has established itself at the forefront of biotech innovation focused on RNA modifications. Their flagship project, STC-15, is the first RNA-modifying enzyme inhibitor to reach human trials, demonstrating promising results.
Recently, the company announced it has raised $56 million in a Series C funding round, exclusively supported including Pfizer Ventures and M Ventures. The previous Phase 1 clinical trials showed durable tumor regression across various sarcoma subtypes, signaling potential breakthroughs in effective cancer therapies.
The funds will be utilized to accelerate the development of STC-15 and expand STORM’s clinical research initiatives. This financial boost underscores the confidence investors have in the company’s innovative approach toward cancer treatment.
As a result, STORM Therapeutics is poised to make significant strides in the biotech field. This funding not only enhances R&D capabilities but also strengthens its position in the competitive landscape of cancer therapeutics, potentially saving lives with advanced treatment options.
Related News
- Tech Company Outlines Principles for AI Policy and Advocacy
- Edge Mobile App Transforms Browsing Experience with New AI Features
- NASA Launches Ambitious Project for Nuclear-Powered Spacecraft
- OpenAI Unveils GPT-5.5, Elevating ChatGPT to New Autonomous Heights
- Iceye Seeks €250 Million Amid Growing Defense Demand
- Fairboard Launches to Address Equity Gaps in AI Medical Devices